Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 28/03/2017

Debbie Rigby looks at the latest in research news Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes This review provides an expert opinion on dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes. Dapagliflozin and other SGLT2

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Teal questions pharmacist UTI programs

because much of the time, I think they’re giving antibiotics for things that are not UTIsPolitician says "I think" and…

Michael Hewson

Medics to ‘fight’ Doctor of Pharmacy title

Yet right now there are far too many reports from overseas of patients being unsure whether their care is from…

Michael Hewson

In scarce supply

I love a good joke.

Evan Nickols

Concurrent funding for aged care pharmacists and RMMRs needed

I understood that was to happen as a gradual changeover and not an abrupt cessation. Currently we do not have…

Jenny Gowan

Research Roundup

Previous Forum: Meningococcal vaccine

Next Hidden population at thunderstorm asthma risk

Ceramides: what are they and why are they important?

In the beginning

The signs of ageing

Hyperpigmentation

MENU

Previous Forum: Meningococcal vaccine

Next Hidden population at thunderstorm asthma risk

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.